Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.890
+0.080 (2.10%)
Aug 23, 2024, 4:00 PM EDT - Market closed
Arbutus Biopharma Employees
Arbutus Biopharma had 73 employees as of December 31, 2023. The number of employees decreased by 25 or -25.51% compared to the previous year.
Employees
73
Change (1Y)
-25
Growth (1Y)
-25.51%
Revenue / Employee
$137,822
Profits / Employee
-$1,055,986
Market Cap
734.36M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Fulgent Genetics | 1,184 |
CureVac | 1,172 |
Standard BioTools | 539 |
Scholar Rock Holding | 150 |
Stoke Therapeutics | 110 |
Silence Therapeutics | 109 |
Alumis | 109 |
Nuvation Bio | 51 |
ABUS News
- 23 days ago - Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update - GlobeNewsWire
- 7 weeks ago - Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity - Seeking Alpha
- 2 months ago - Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels - GlobeNewsWire
- 2 months ago - Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure - GlobeNewsWire
- 2 months ago - Arbutus Distributors Ltd. News Release - GlobeNewsWire
- 3 months ago - Arbutus to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire